- Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559
- Actuate Therapeutics Announces Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
- Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug)
- Affimed N.V. announced abstract on Ph 2 LuminICE-203 study of acimtamig + AlloNK® (AB-101) and two abstracts on AFM24 + atezolizumab in NSCLC
- Alligator Bioscience Presents OPTIMIZE-1 Biomarker Data
- Allogene Therapeutics Announces Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
- Antengene to Present Clinical Results from 2 Studies in CPI-resistant Solid Tumors
- Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Trial
- Arcus Biosciences to Present First Combination Data for Casdatifan + Cabozantinib in an Oral Presentation
- Arvinas Announces Results from the VERITAC-2 Trial for Oral Presentation
- Ascentage Pharma Announces Clinical Data of Lisaftoclax in Venetoclax-Refractory Patients
- Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term OS in Metastatic HSPC
- AstraZeneca to present 80 abstracts from 20 approved and potential new medicines
- Bantam Pharmaceutical to Present poster to ongoing Ph 1 trial of BTM-3566 in patients with R/R mature B-cell lymphomas
- Beigene to share 23 abstracts featuring new data across its hematology and solid tumor portfolio
- Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Ph 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC
- Bicycle Therapeutics Announces Poster Presentations
- BioAtla Announces Poster Presentation from Ph 2 trial of ozuriftamab vedotin (BA3021) in patients with heavily pretreated SCCHN
- BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data
- Candel Therapeutics Presents Positive Ph 3 CAN-2409 Results in Localized Prostate Cancer
- CARsgen to present Satri-cel data
- CCM Biosciences announces the presentation of its next-gen FLT3 inhibitor drug program for AML
- Corcept To Present Data From Pivotal Ph 3 Rosella Trial Of Relacorilant In Platinum-resistant Ovarian Cancer
- Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Ph 2b REZILIENT1 Trial of Zipalertinib
- Daiichi Sankyo to present new clinical research across oncology portfolio with more than 20 abstracts in multiple cancers
- Eli Lilly announced data from studies of imlunestrant, olomorasib, LY4170156, and Verzenio
- Eisai to present clinical research across its oncology portfolio and pipeline
- Exelixis Announces Results from Ph 1b/2 STELLAR-002 Trial of Zanzalintinib + Immune Checkpoint Inhibitors in Advanced Kidney Cancer
- FORE Biotherapeutics to Present Plixorafenib Abstract
- Foundation Medicine to Present Over 15 Abstracts
- Genmab to Highlight New Data Evaluating Rina-S and epcoritamab
- GV20 Therapeutics to Present Updated Ph 1 Monotherapy Data on GV20-0251
- HUTCHMED presents data of several assets including savolitinib, ranosidenib, fruquintinib, and surufatinib
- ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy
- ImPact Biotech Announces Late-Breaking Podium Presentation Highlighting ENLIGHTED Study Interim Analysis
- IMUNON Announces Oral Presentation Highlighting Survival Data from Ph 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
- Iovance Announces 5-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma
- Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib
- Menarini Group Presents Updated Data of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC)
- Merck announced the presentation of new oncology data across more than 12 tumor types
- Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations
- Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
- Mythic Therapeutics to Present Efficacy Data from Ph 1 KisMET-01 Study of MYTX-011 in NSCLC
- Novita Pharmaceuticals Announces Oral Presentation of Ph 2 NP-G2-044 Data
- Novocure to Present Results from the Ph 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
- Nuvalent to Present Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330
- Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive NSCLC
- Obsidian Therapeutics to Present Clinical Data from OBX-115 for Patients with Advanced Melanoma in Oral Presentation
- Oncolytics Biotech® to Present New Clinical Trial Data Showing Pelareorep’s Immune Activation Capabilities
- OSE Immunotherapeutics and Boehringer Ingelheim to Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity in 2 Ongoing Trials
- PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune HPV
- Pfizer to present more than 60 abstracts, including 15 oral and rapid oral presentations to highlight advancements across oncology portfolio
- Rakuten Medical Announces Trial in Progress Poster Presentation and Enrollment Expansion to Taiwan for Global Ph 3 ASP-1929-381
- Regeneron announces Initial Results from Linvoseltamab + Carfilzomib/Bortezomib in Earlier Lines of Treatment for R/R Multiple Myeloma
- Rigel Announces Poster Presentations from the GAVRETO® (pralsetinib) Ph 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors and supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML
- Sapience Therapeutics Announces Oral Presentation of Lucicebtide Ph 2 Results
- Servier announces Presentations in IDH-Mutated Cancers
- Syncromune Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Ph 1 Data for Metastatic Prostate Cancer
- Transgene to Present 24-month Disease-Free Survival Data from All Patients in Ph I Part of Trial of TG4050
- Verastem Oncology to present the updated RAMP 205 data as well as updated data on VS-7375
- Verismo Therapeutics to present overview of ongoing STAR-101 Ph 1 clinical study
- Volastra Announces Initial Data from First-in-Human Ph 1/2 Trial of VLS-1488
- Xilio Therapeutics to Present Updated Ph 2 Data for Vilastobart in Combination with Atezolizumab in Patients with MSS CRC
- Zai Lab to Present Data from Ph 1 Trial of ZL-1310
- Zentalis Pharmaceuticals to present Ph 1/2 trial of azenosertib in combination with encorafenib and cetuximab in patients with metastatic BRAF V600E mutant CRC
- Zymeworks Inc. announced multiple presentations related to oncology programs